



Conversion From Calcineurin Inhibitors to Mammalian Target of Rapamycin Inhibitors in Kidney Transplant Recipients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

OPEN ACCESS

Edited by:

Soldevila Gloria, National Autonomous University of Mexico, Mexico

Reviewed by:

Josefina M. Alberu, Tecnológico de Monterrey, Mexico Jianghua Chen, Zhejiang University, China

*Correspondence:

Xianding Wang xiandingwang@outlook.com Tao Lin kidney5@163.com [†]These authors share first authorship

Specialty section:

This article was submitted to Alloimmunity and Transplantation, a section of the journal Frontiers in Immunology

Received: 03 February 2021 Accepted: 16 August 2021 Published: 03 September 2021

Citation:

Zeng J, Zhong Q, Feng X, Li L, Feng S, Fan Y, Song T, Huang Z, Wang X and Lin T (2021) Conversion From Calcineurin Inhibitors to Mammalian Target of Rapamycin Inhibitors in Kidney Transplant Recipients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Front. Immunol. 12:663602. doi: 10.3389/fimmu.2021.663602 Jun Zeng^{1,2†}, Qiang Zhong^{1,2†}, Xiaobing Feng^{1,2}, Linde Li^{1,2}, Shijian Feng^{1,2}, Yu Fan^{1,2}, Turun Song^{1,2}, Zhongli Huang^{1,2}, Xianding Wang^{1,2*} and Tao Lin^{1,2*}

¹ Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China, ² Organ Transplantation Center, West China Hospital, Sichuan University, Chengdu, China

Background: A systematic review and meta-analysis were performed to investigate the efficacy and safety of conversion from calcineurin inhibitors (CNIs) to mammalian target of rapamycin inhibitors (mTORi) in kidney transplant recipients (KTRs).

Methods: MEDLINE, EMBASE, PubMed, and Cochrane Library were searched to identify randomized controlled trials (RCTs) that compared the continuation of CNI with conversion to mTORi therapy.

Results: Twenty-nine RCTs (5,747 KTRs) were included in our analysis. Meta-analysis of the glomerular filtration rate (SMD 0.20; 95%Cl 0.10–0.31; P<0.01) and malignancy (RR 0.74; 95%Cl 0.55–0.99; P=0.04) demonstrated a significant advantage of mTORi conversion over CNI continuation. However, the risk of acute rejection (RR 1.58; 95%Cl 1.22–2.04; P<0.01), infection (RR 1.55; 95%Cl 1.01–1.31; P=0.04), proteinuria (RR 1.87; 95%Cl 1.34–2.59; P<0.01), leukopenia (RR 1.56; 95%Cl 1.27–1.91; P<0.01), acne (RR 6.43; 95%Cl 3.43–12.04; P<0.01), and mouth ulcer (RR 11.70; 95%Cl 6.18–22.17; P<0.01) were higher in the mTORi group. More patients in the conversion group had to discontinue study medication (RR 2.52; 95%Cl 1.75–3.63; P<0.01). There was no significant difference between the two groups with regard to death, graft loss, diabetes, chronic allograft nephropathy, and interstitial fibrosis/tubular atrophy.

Conclusions: Posttransplant patients have a better graft function and lower incidence of malignancy after conversion from CNI to mTORi therapy. However, this conversion strategy may be prevented by the higher drug discontinuation rate due to mTORi-

1

associated adverse events, such as more acute rejection, infection, proteinuria, leukopenia, acne, and mouth ulcer, indicating that conversion therapy may only be a treatment option in selected patients.

Keywords: calcineurin inhibitor, mammalian-target-of-rapamycin inhibitor, kidney transplantation, conversion, meta-analysis

INTRODUCTION

Most kidney transplant recipients (KTRs) currently receive calcineurin inhibitor (CNI) therapy, which has remarkably reduced acute rejection (AR) episodes and improved early graft survival (1). However, long-term CNI exposure may induce irreversible nephrotoxicity, resulting in progressive graft dysfunction (2, 3). The CNI can also promote cardiovascular events and malignancies, which are the leading causes of premature death with a functioning graft (4, 5). This discrepancy has prompted investigations into CNI retention strategies, which maintain adequate immunosuppressive effects without compromising safety (6).

Mammalian target of rapamycin inhibitors (mTORi) are new immunosuppressants that exhibit little or minimal nephrotoxicity (7–9). The dual immunosuppressive and antineoplastic properties of mTORi offer a distinct advantage for this class of drugs in the treatment of patients who receive kidney transplant (10, 11). Nevertheless, major concerns associated with the *de novo* introduction of mTORi include the risk of AR, impaired wound healing, and prolonged delayed graft function (DGF), limiting the adoption of mTORi as a first-line immunosuppressant (9, 12, 13).

Thus, increasing interest has been directed toward exploiting the synergistic actions of CNIs and mTORi by administering the CNI at the initial stage of high-risk AR after transplantation and then converting it into mTORi before the onset of CNI-induced irreversible nephrotoxicity (14). Evidence regarding the clinical benefit of this conversion strategy is conflicting. Budde et al. (15) demonstrated that mTORi combined with CNI withdrawal improved kidney function while maintaining efficacy and safety. In contrast, several studies reported that mTORi therapy not only did fail to show any overall clinical benefit but also mTORi conversion was associated with more adverse events (16) and discontinuations (17). Thus, further evidence for the validity of mTORi conversion strategy is urgently needed (18). Our study aimed to systematically identify and evaluate the currently available evidence from randomized controlled trials (RCTs) on the outcomes of conversion from the CNI to mTORi for KTRs.

MATERIALS AND METHODS

Our systematic review was conducted and reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (19).

Eligibility Criteria

Studies were eligible if they met the following criteria: (a) RCTs of conversion from CNIs to mTORi maintenance immunosuppressive regimen; (b) participants were the recipients of a single organ kidney transplant (first or repeat) from a living or deceased donor; (c) initial immunosuppression consisted of a CNI but not an mTORi; and (d) KTRs were randomly assigned to either continue with current CNI therapy or be converted from the CNI to mTORi. Dose modifications of CNIs, mTORi, and other concomitant immunosuppressants were permissible after randomization. Randomized trials with less than 20 cases in each group or abstracts of major transplant conferences were excluded. KTRs with a history of malignancy (other than adequately treated non-melanoma skin carcinoma) before randomization were excluded. To minimize participant overlap, when the same study was reported many times, the study with long follow-up period and complete case report was identified as the primary data source.

Search Strategy

MEDLINE, EMBASE, PubMed, and Cochrane Library were searched from the start date of each resource up to November 12, 2020 (the last literature search) using logical combinations of relevant keywords and medical subject headings that contained all spellings of the following terms: kidney transplantation, calcineurin inhibitor, CNIs, tacrolimus, cyclosporine, conversion, mTORi, sirolimus, and everolimus. No restrictions regarding the language of the publication, age of KTRs, or concomitant immunosuppressants were applied. The results were supplemented by manually searching reference lists of relevant reviews and included articles. All citations identified by this search strategy were evaluated by two independent reviewers (JZ and QZ) using titles, abstracts, and, where required, the full text to determine eligibility.

Outcome Measures

The primary endpoints were graft function, AR, graft loss, and death. The secondary outcomes were adverse events (AEs), infections, malignancies, and discontinuation of medication.

Data Extraction

Eligible RCTs were referred to throughout this paper by the first author (JZ and QZ) and the year of the earliest peer-reviewed publication. Data extraction was independently performed by

Abbreviations: AE, adverse event; AR, acute rejection; ATG, anti-thymocyte globulin; CI, confidence interval; CNI, calcineurin inhibitor; CsA, cyclosporine A; DGF, delayed graft function; eGFR, estimated glomerular filtration rate; EVL, everolimus; IF/TA, interstitial fibrosis/tubular atrophy; KTR, kidney transplant recipient; MPA, mycophenolic acid; mTORi, mammalian target of rapamycin inhibitor; MD, mean difference; PTLD, posttransplant lymphoproliferative disease; RCT, randomized controlled trial; RR, risk ratio; SMD, standard mean difference; SRL, sirolimus; TAC, tacrolimus.

Conversion From CNIs to mTORi

two reviewers (JZ and QZ) using a predesigned form on which study design, participant characteristics, interventions, and outcome data were recorded. Missing information was requested from the trial authors or sponsors. They met to combine their findings, and the information was subsequently entered into Review Manager (RevMan) (Version 5.4, Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration).

Quality Assessment and Statistical Analyses

Cochrane Collaboration's tool was used to assess the risk of bias of randomized controlled trials (20). RevMan 5.4 was utilized for the execution of the meta-analysis. Dichotomous outcomes were expressed as risk ratios (RRs) with 95% confidence intervals (CIs), and continuous variables were expressed as mean differences (MDs) with 95% CI. Data were pooled using the standardized mean difference (SMD) as the summary effect size metric. P<0.05 was considered statistically significant. Meta-analysis was conducted using the fixed effect model in the absence of heterogeneity; otherwise, the random effect was applied. Heterogeneity was quantified *via* the Cochrane Q (P<0.1) and I² statistics (I²>50%). If heterogeneity existed, a sensitivity analysis was performed to explore possible sources of heterogeneity.

RESULTS

Search and Selection

The search and selection flow chart is illustrated in **Figure 1**. Initial literature searches identified 1,488 citations across all databases. The titles and abstracts were reviewed, followed by full-text review of potentially eligible articles and abstracts, of which 29 RCTs met the inclusion criteria (15, 17, 21–47). The baseline overview of included studies is reported in **Table 1**.

Description of Eligible Trials

There were 29 eligible RCTs, in which a total number of 5,747 KTRs were included, whose characteristics are summarized in **Table S1**. Among these 29 trials, 22 trials reported the time of conversion to mTORi within 6 months after transplantation; the rest were more than 6 months. A total of 16 RCTs reported the impressive therapy of conversion from the CNI to everolimus. The patient sample size ranged from 49 to 830, and follow-up duration was from 6 to 24 months.

Quality of Included Trials

The quality of the 29 clinical trials was evaluated by Cochrane Collaboration's tool (**Figure S1**). A total of 14 studies exhibited an adequate random sequence generation process, 15 trials described the methods used for allocation concealment, 2 RCTs illustrated performance bias, and 4 studies had unreported data. In short, the studies included had low to moderate risk of bias.

Primary Endpoints

The meta-analysis results of the primary endpoints are reported in **Figures 2** and **3**. A total of 22 trials reported renal function; the meta-analysis of the estimated glomerular filtration rate (eGFR) demonstrated a statistically significant advantage for mTORi conversion over CNI continuation (SMD 0.20; 95%CI 0.10–0.31; P<0.01) in **Figure 2A**. A total of 28 trials reported AR; we found that patients converted to mTORi were at a higher risk of developing AR (RR 1.58; 95%CI 1.22–2.04; P<0.01) in **Figure 2B**. A total of 22 trials reported graft loss; there was no difference between patients converted to mTORi and those remaining on the CNI (RR 1.14; 95%CI 0.75–1.74; P=0.53) in **Figure 3A**. A total of 22 trials reported mortality; we also found that there was no statistical difference in mortality between the mTORi conversion group and the CNI continuation arm (RR 0.99, 95%CI 0.64–1.55; P=0.97) in **Figure 3B**.

Secondary Endpoints

Sixteen studies described the adverse events (AEs) and serious adverse events (sAEs). Despite the comparable rate of AEs (RR 1.03; 95%CI 0.99-1.06; P=0.11), patients converted into mTORi had a significantly higher risk to have sAEs (RR 1.23; 95%CI 1.09-1.39; P<0.01; Figure S2A). Twenty-one RCTs reported the drug discontinuation from AEs. There was a greater risk of drug discontinuation in patients who converted to mTORi compared with those on the CNI (RR 2.52; 95%CI 1.75-3.63; P<0.01; Figure S2B). Sixteen trials described infections, and eight trials described serious infections (defined as requiring hospitalization). We found that there was a higher risk of infections and serious infections in the mTORi conversion group compared with the remaining CNI group (RR 1.15; 95%CI 1.01-1.31; P=0.04; Figure S3A; RR 1.17; 95%CI 1.05-1.30; P<0.01; Figure S3B, respectively). Fifteen studies reported on cancer outcomes. Patients converted from the CNI to mTORi had lower risk of malignancy compared with those continuing on the CNI therapy (RR 0.74; 95%CI 0.55-0.99; P=0.04; Figure S4A). In addition to these advantageous results, we also found other adverse consequences brought about by the mTORi therapy, including proteinuria (RR 1.87; 95%CI 1.34-2.59; P<0.01; Figure S4B), mouth ulcer (RR 11.70; 95%CI 6.18-22.17; P<0.01; Figure S4C), anemia (RR 1.55; 95%CI 1.26-1.89; P<0.01; Figure S5A), leukopenia (RR 1.56; 95%CI 1.27-1.91; P<0.01; Figure **S5B**), thrombocytopenia (RR 2.45; 95%CI 1.13-5.35; P=0.02; Figure S5C), dyslipidemia (RR 1.41; 95%CI 1.27-1.58; P<0.01; Figure S6A), acne (RR 6.43; 95%CI 3.43-12.04; P<0.01; Figure S6B), diarrhea (RR 1.46; 95%CI 1.28-1.67; P<0.01, Figure S7A), and edema (RR 1.49; 95%CI 1.14-1.93; P<0.01; Figure S7B). In Figure S8, there were no differences in diabetes and interstitial fibrosis/tubular atrophy (IF/TA) between the mTORi conversion group and the CNI continuation group. On the other hand, there was no significant difference between the two groups with regard to CMV or BKV infection (Figure S9), chronic allograft nephropathy (increased serum creatine), gastroenteritis, pyrexia, posttransplant lymphoproliferative disease (PTLD), and wound-related problem (Table S3).

DISCUSSION

The meta-analysis of the 29 eligible RCTs (involving 5,747 KTRs) demonstrated that the conversion from the CNI to



Study	Year	Design	Sample size	Time since transplantation	Follow-up (months)			Results		
						eGFR	Death	Graft loss	AR	AEs
Tönshoff	2019	RCT	52/54	4–6 weeks	12	Yes	No	No	Yes	Yes
Taber	2019	RCT	30/30	3 months	12	Yes	No	No	Yes	Yes
Brakemeier	2019	RCT	51/24	7 weeks	6	Yes	No	No	Yes	Yes
Haynes	2018	RCT	197/197	6 months	18	Yes	Yes	Yes	Yes	Yes
Bouamar	2018	RCT	30/30	3 months	12	Yes	Yes	Yes	Yes	Yes
Fijter	2017	RCT	359/356	10-14 weeks	24	Yes	Yes	Yes	Yes	Yes
Budde	2017	RCT	171/165	3 months	12	Yes	Yes	Yes	Yes	Yes
Bemelman	2017	RCT	96/89	6 months	24	NR	Yes	Yes	Yes	Yes
Pretagostini	2016	RCT	24/25	1-month	12	NR	NR	NR	Yes	Yes
Felix	2016	RCT	60/59	3 months	24	NR	Yes	NR	Yes	Yes
Cruzado	2016	RCT	35/36	6 months to 3 years	24	Yes	Yes	No	No	Yes
Rostaing	2015	RCT	96/98	3–4 months	12	Yes	No	Yes	Yes	Yes
Mjörnstedt	2015	RCT	92/90	7 weeks	24	Yes	Yes	No	Yes	Yes
Sandes-Freitas	2015	RCT	48/45	3 months	24	Yes	NR	NR	Yes	NR
Budde	2015	RCT	46/47	NR	12	Yes	Yes	No	No	Yes
Silva	2013	RCT	97/107	3 months	24	Yes	Yes	Yes	Yes	Yes
Chhabra	2013	RCT	123/64	12 months	24	Yes	Yes	Yes	Yes	Yes
Bansal	2013	RCT	31/29	2 months	6	Yes	NR	NR	Yes	Yes
Mjörnstedt	2012	RCT	102/100	7 weeks	12	Yes	Yes	No	Yes	Yes
Weir	2011	RCT	148/151	1–6 months	24	Yes	Yes	Yes	Yes	Yes
Holdaas	2011	RCT	127/123	6 months	24	Yes	Yes	Yes	Yes	Yes
Heilman	2011	RCT	62/60	1-month	24	Yes	Yes	Yes	Yes	Yes
Budde	2011	RCT	154/146	4.5 months	12	Yes	Yes	No	Yes	Yes
Guba	2010	RCT	69/71	10–24 days	12	Yes	Yes	Yes	Yes	Yes
Schena	2009	RCT	555/275	6–120 months	24	Yes	NR	Yes	Yes	Yes
Lebranchu	2009	RCT	95/97	3 months	12	Yes	No	Yes	Yes	Yes
Bemelman	2009	RCT	38/39	6 months	24	Yes	NR	NR	Yes	Yes
Liu	2007	RCT	56/54	> 12 months	24	NR	NR	No	No	NR
Stallone	2005	RCT	34/50	12–36 months	24	NR	NR	NR	No	Yes

TABLE 1 | Baseline overview of 29 included studies.

eGFR, estimated glomerular filtration rate; AR, acute rejection; AEs, adverse events; NR, not reported.

mTORi after kidney transplantation was associated with an improvement in graft function and a reduced incidence of malignancy. There was no significant difference between the groups with respect to IF/TA or chronic allograft nephropathy, indicating that the improvement in graft function after conversion may primarily be due to effects other than structural improvement (48). Ten years ago, mTOR inhibitors were more commonly used, but only 1.9% of recipients were prescribed with them at transplant in 2016, increasing to 4.3% at 1-year posttransplant (49). Current studies reported that the combination of low-dose CNI (tacrolimus) and everolimus can make the difference in order to obtain the best clinic benefit for KTRs (50). Nevertheless, conversion to mTORi therapy may be prevented by the high discontinuation rate (51) due to the intolerable AEs, such as the development of serious infections, AR, mouth ulceration, proteinuria, anemia, leucopenia, thrombocytopenia, dyslipidemia, acne, diarrhea, and edema. All of these changes were statistically significant between the two groups. Thus, the application of mTORi conversion must be weighed during clinical decision-making, with the potential benefits and risks carefully assessed for each KTR.

Previous systematic review had suggested that conversion to sirolimus was associated with an improvement in short-term renal function, while none of the identified studies investigated everolimus (18, 52). Similarly, Lim et al. (53) reviewed RCTs comparing delayed conversion from CNIs to mTORi indicating that patients converted to mTORi up to 1-year posttransplant had higher GFR compared with those remaining on the CNI. Those findings were highly consistent with our meta-analysis, but we also found that there was no difference in CMV and BKV infection, and no difference in new-onset diabetes. Wolf et al. (54) concluded that the incidence of infections is lower when mTORi is combined with a CNI compared to a standard CNI therapy following renal transplantation, while we found that mTORi conversion therapy had more risk of infections.

In this systematic review, we identified all mTORi conversion RCTs involving both sirolimus and everolimus with heterogeneous treatment and varying follow-up period. We included the RCTs with more than 20 cases in each group, which made the evidence in this review stronger and more convincing. We also evaluated some outcomes (graft function, acute rejection, graft loss, death) and some secondary outcomes that are not commonly reported in other systematic reviews such as drug discontinuation and adverse events. Consequently, the current study provides critical information to guide clinical decision-making on the mTORi conversion strategy after kidney transplantation.

Nevertheless, there were potential caveats limiting the generalizability of our findings. First, besides mTORi-induced AEs, the open-label nature of the 29 RCTs may have



contributed to the high discontinuation rate in the conversion group. KTRs in the conversion group underwent a major change in immunosuppression after successful transplantation, and the KTRs may have tended to revert to their original immunosuppression due to the perceived limited efficacy or newly emergent AEs. Second, the 29 RCTs differed with respect to the baseline graft function, induction therapy, conversion time after transplantation, indication for conversion, strategy for conversion (abrupt vs. stepwise), and target immunosuppressant exposure. There may be selection and measurement bias, either of which may ultimately affect the validity of the study results. Third, all KTRs received mycophenolic acid (MPA)-based immunosuppression. It has been documented that CNIs, but not mTORi, inhibit MPA enterohepatic recirculation, resulting in a 50% lower MPA exposure (55). In most of the eligible RCTs, MPA was administered at a fixed dose; after conversion, more KTRs in the conversion group may have been overexposed to MPA, ultimately contributing to the reported AEs. Fourth, most RCTs

focused on KTRs with low-to-moderate immunological risk; therefore, our results cannot be extended to high-risk KTRs. Fifth, due to the difference in the number of included cases, we did not distinguish the difference between CsA and TAC conversion.

Determining the optimal timing or indication for mTORi conversion requires a balance between avoiding the high rejection risk in the initial posttransplant period and minimizing the progressive development of CNI-related nephrotoxicity. Conversion \geq 1-year posttransplant may be insufficient to prevent progression to graft dysfunction, except in KTRs with normal graft function and without proteinuria (14). Conversion in the first 6 months after transplantation seems appropriate for maintenance therapy in KTRs after careful screening (14). Refining selection criteria may help both in identifying patients who will profit most from switching and in alleviating the need to reintroduce CNI therapy. Primarily based on the current consensus, the target population for mTORi

Shudy or Subgroup Mean SD Total Melight V. Random.95%, Cl Year V. Random.95%, Cl Year Taber 2019 35 10.8 51 42.3 24.8% -0.47 (10-66, 0.02) 2019 Taber 2019 53 13 30 56 15 30 2.7% -0.19 (10-60, 0.02) 2019 Haynes 2018 53.5 16.8 197 5.0 156 157.5 155 17 155 5.7% 0.50 (10-0.71) 2019 Filter 2017 6.38 19.8 46 82.2 16.6 47.3% 0.24 (10.09, 0.39) 2017 Filter 2017 6.52 15.9 65 15.9 65.0.2 15.3 84.9% 0.12 (-0.16, 0.40) 2015 Sandes Freitas 2015 6.1 19.7 72.5 15.0 84.9% 0.12 (-0.16, 0.40) 2013 Miorstedt 2012 7.3 17.1 100 61.65 29.2 64.9% 0.29 (-0.06, 10.09) 2013	Study corp Mean SD Total Mean SD Total Weight IV. Random S% C1 Vear IV. Random Taber 2019 95 14 30 56 15 30 2.7% 0.20 [-0.30, 0.71] 2019 - Taber 2019 55 13 30 56 16 30 2.7% 0.20 [-0.30, 0.71] 2019 - - Boumanz 2018 53 15.8 16.8 197 5.0% 0.05 [-0.14, 0.25] 2018 - - - - - - 0.21 (0.06, 0.39) 2017 - - - - 0.24 (0.06, 0.39) 2017 - - - - - 0.24 (0.06, 0.39) 2017 - - - - 0.24 (0.06, 0.39) 2017 - - - - 0.24 (0.06, 0.39) 2017 - - - 0.24 (0.06, 0.39) 2015 - - - 0.24 (0.46, 0.49) 2015 - - - <th>n. 95% Cl</th>	n. 95% Cl
Brakemeier 2019 36,5 10.8 51 42 13 24 2.8% -0.47 (-0.96, 0.02) 2019 Bouamar 2018 53 16.8 197 52 16.8 197 22 -0.19 (-0.20, 0.21) 2101 Budde 2017 7.7 19.4 11 62.5 17.6 65.5 16.6 197 62.5 22.4 359 57.% 0.20 (0.90, 0.39) 2101 Budde 2017 76.5 22.4 359 57.4 0.24 (0.90, 0.39) 2101 - Budde 2015 60.3 19.7 92 57.4 20.2 94.8% 0.31 (-0.16, 0.43) 2015 Gradamg 2015 62.1 15.9 96 0.2 15.3 98 4.9% 0.12 (-0.16, 0.40) 2015 Gradamg 2013 66.2 23.7 72.3 107 75.5 107.7 75.4 107.7 75.4 10.404.5 10.9 10.3 11.4 45.9 14.4 45.9 10.001.0.3 10.1 11.4 14.5 12.3 15.5 10.001.0.3.0.3 20.1 10.4 10.4	Brakemeier 2019 36.5 10.8 51 42 13 24 2.8% -0.47 [-0.96, 0.02] 2019 Bouamar 2018 53 16.3 30 56 15 30 2.7% -0.19 [-0.70, 0.32] 2019 Bouamar 2018 53 15.3 30 56 16 30 2.7% -0.19 [-0.70, 0.32] 2018 Budde 2017 7.1.7 19.4 171 62.5 16.6 197 6.0% 0.05 [-0.14, 0.25] 2018 Budde 2017 7.1.7 19.4 171 62.5 16.6 197 6.0% 0.05 [-0.14, 0.25] 2017 Budde 2017 7.1.7 19.4 171 62.5 17 16.5 5.7% 0.26 [0.00, 0.39] 2017 7 Budde 2015 63.1 18.8 46 58.2 16.6 47 3.5% 0.30 [-0.16, 0.43] 2015 7 Rostaing 2015 52.1 15.9 96 50.2 15.3 98 4.9% 0.12 [-0.16, 0.4	
laber 2019 59 14 30 56 15 30 2.7% 0.20 0.20 0.70 0.21 0.70 0.70 0.70 <th0.70< th=""> 0.21 <th0.< td=""><td>Laber 2019 B9 14 30 66 15 30 2/% U.21 <thu.21< th=""> <thu.21< th=""> <thu.21< th=""></thu.21<></thu.21<></thu.21<></td><td></td></th0.<></th0.70<>	Laber 2019 B9 14 30 66 15 30 2/% U.21 U.21 <thu.21< th=""> <thu.21< th=""> <thu.21< th=""></thu.21<></thu.21<></thu.21<>	
bodumina 2010 53 13 30 26 16 19 20.19 -0.19 10.10 10.23 2018 Haynes 2016 53 16.8 197 52.5 17 165 5.7% 0.50 10.20 10.21 10.14 0.25 10.14 0.25 10.00 0.39 20.17 10.14 0.25 10.7 10.5 10.7 10.5 10.7 10.5 10.00 0.39 20.17 10.16 0.43 20.15 10.00 0.39 20.15 10.00 0.39 10.16 0.43 20.15 10.16 0.43 20.15 10.16 0.43 20.15 10.16 0.43 20.15 10.16 0.43 20.15 10.16 0.43 20.15 10.16 0.43 20.15 10.16 0.43 20.15 10.16 0.43 20.15 10.16 0.43 20.15 10.16 10.16 20.15 10.16 10.16 20.16 10.16 20.15 10.16 10.16 20.16 10.16 20.16 10.16 20.16 10.16 10.16 10.16 1	Boularmar 2010 Boularm	
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	Haylmas Aulo 35.3 16.6 19 26.6 16.6 19 8.0% 0.05	
Double 2017 File Disk Disk <thdisk< th=""> Disk Disk</thdisk<>	Dudde 2017 17.1 19.4 19.2 35.6 67.7 0.24 (10.6) 0.39 (25.01.3) Budde 2015 63.5 19.8 55.6 67.76 0.24 (10.6) 0.39 (25.01.3) 2017 Budde 2015 63.8 19.8 56 67.76 0.24 (10.6) 0.39 (25.01.3) 2017 Budde 2015 60.1 19.7 92 57.4 0.24 (10.6) 0.39 (25.01.3) 2015 Rostang 2015 52.1 15.9 96 50.2 19.4 48 0.12 (-0.16.0.40) 2015 Chabra 2013 66.5 23.7 123 60 12.2 64 4.6% 0.28 [-0.60.16] 2015 Chabra 2013 66.2 23.7 70.7 70.7 71.7 10.7 50.7 0.07.2 0.14 [-0.46.010] 2013 Bansal 2013 66.2 23.7 70.7 70.7 70.7 70.7 70.7 70.7 70.7 70.7 70.7 70.7 70.7 70.7 70.7 70.7 70.7	
Budge 2015 638 198 46 582 166 47 3.5% 0.30 [-010.071] 2015 Morrated: 2015 60.1 197 92 57.4 202 90 44% 0.315.0 16 0.43] 2015 Frontaing 2015 52.1 15.9 96 50.2 15.3 98 49% 0.12 [-016.040] 2015 Frontaing 2015 52.1 15.9 96 50.2 15.3 98 49% 0.12 [-016.040] 2015 Chabra 2013 66.5 23.7 123 60 18.2 64 49% 0.29 [-001.061] 2013 Bansal 2013 66.5 23.7 123 60 18.2 64 49% 0.29 [-001.061] 2013 Bansal 2013 66.5 23.7 123 60 18.2 64 49% 0.29 [-001.061] 2013 Bansal 2013 66.5 23.7 17.3 17.6 100 50% 0.15 [-013.043] 2011 Holdaas 2011 75.5 192 148 71.2 23.5 151 50% 0.09 [-015.034] 2011 Holdaas 2011 75.5 192 148 71.2 23.5 151 56% 0.20 [-013.043] 2011 Holdaas 2011 64.5 2.9 62 62.8 21.6 60 40% 0.06 [-03.041] 2011 Guba 2010 64.5 25.2 69 53.4 118 71 4.2% 0.51 [0.17.044] 2010 Guba 2010 64.5 25.2 69 53.4 118 71 4.2% 0.51 [0.17.044] 2010 Guba 2010 64.5 25.2 69 53.4 118 71 4.2% 0.51 [0.17.044] 2010 Guba 2010 64.5 25.2 69 53.4 118 71 4.2% 0.51 [0.16, 1.07] 2009 Schena 2009 55 1.4 555 57.7 15.4 275 6.7% 0.04 [-0.30, 0.31] 2009 Faretoroverail effect: Z = 3.83 (P = 0.0001); P = 66% Test for overail effect: Z = 3.83 (P = 0.0001); P = 66% Test for overail effect: Z = 3.83 (P = 0.0001); P = 66% Test for overail effect: Z = 3.83 (P = 0.0001); P = 66% Test for overail effect: Z = 3.83 (P = 0.0001); P = 66% Test for overail effect: Z = 3.83 (P = 0.0001); P = 66% Test for overail effect: Z = 3.83 (P = 0.0001); P = 66% Test for overail effect: Z = 3.83 (P = 0.0001); P = 66% Test for overail effect: Z = 3.83 (P = 0.0001); P = 66% Test for overail effect: Z = 3.83 (P = 0.0001); P = 66% Test for overail effect: Z = 3.83 (P = 0.0001); P = 66% Test for overail effect: Z = 3.83 (P = 0.0001); P = 66% Test for overail effect: Z = 3.83 (P = 0.0001); P = 66% Test for overail effect: Z = 3.83 (P = 0.0001); P = 66% Test for overail effect: Z = 3.83 (P = 0.0001); P = 66% Test for overail effect: Z = 3.83 (P = 0.0001); P = 66% Test for overail effect: Z = 3.83 (P = 0.0001); P = 66% Test for overail effect: Z = 3.83 (P = 0.0001); P = 66%	Budds 2015 63.8 19.8 46 58.2 16.6 47 3.5% 0.30 0.10.071 2015 Mominetz 0015 60.1 19.7 92 57.4 22.2 90 48.% 0.13 0.10.031 2015 Routaing 2015 52.1 15.9 96 59.2 15.3 98 4.9% 0.12 0.10.043 2015 Sandas-Forbacs 2015 63.7 19.3 48 61.1 49.4 55 -0.25 0.66.101 2015 Chabro 2013 65.6 23.7 123 40 18.2 64 4.6% 0.29 0.60.101 2013 Banasi 2013 65.6 23.7 12.3 60 15.2 64 4.6% 0.29 0.01.001 2013 Banasi 2013 65.2 37 70.7 10.7 5.0% 0.57 0.06.100 2013 Migminetic 2017 7.3 17.1 102 7.5.1 107 5.0% 0.57 0.04.10	
$\begin{tabular}{ c c c c c c c c c c c c c c c c c c c$	Mjørnsteti 2015 60.1 19.7 92 57.4 20.2 90 4.8% 0.13 0.16 0.43 2015 Rostaling 2015 52.1 15.9 96 50.2 15.3 98 4.9% 0.12 (-0.16, 0.43) 2015 Rostaling 2015 52.1 15.9 96 50.2 15.3 98 4.9% 0.12 (-0.16, 0.40) 2015 Sandes-Freitas 2015 65.5 2.3 7 12.8 4.4% 0.25 (-0.66, 0.16) 2015 Shwa 2013 66.2 2.5.7 12.0 60 18.2 64 4.6% 0.25 (-0.66, 0.16) 2015 Bansal 2013 66.2 2.5.7 10.7 5.0% 0.18 (-0.46, 0.10) 2013 Mjørnstett 2017 7.3.9 17.1 102 7.1.3 17.6 100 5.0% 0.15 (-0.13, 0.43) 2012 Holdaas 2011 48 12.2 146 14.2 5.3% 0.09 0.5.16	
Rotating 2015 52.1 15.9 96 50.2 15.3 98 4.9% 0.12 0.16 0.12 0.16 0.12 0.16 0.12 0.16 0.12 0.16 0.12 0.16 0.12 0.16 0.12 0.06 0.12 0.06 0.16 0.26 0.06 0.01	Rostang 2015 52.1 15.9 96 50.2 15.3 98 4.9% 0.12 0.16 0.015 Sandas-Fottas 2015 63.7 19.3 48 68.1 14.9 45 35.% 0.25 16.0 101 5 Shandas-Fottas 2013 66.5 23.7 123 60 18.2 64 4.6% 0.25 106.0 101 5 Shava 2013 66.2 23.7 123 60 18.2 64 4.6% 0.25 106.0 101 5 Bansal 2013 86.9 11.8 31 80.6 16.5 29 2.6% 0.57 10.61, 100 2013 Holdmas 2011 73.9 17.1 102 71.3 176 100 5.0% 0.15 0.21 0.43 2011 100 100 101 100 100 101 100 101 100 101 100 101 100 101 100 101 100 1	
Sandes-Freitas 2015 63.7 19.3 48 68.1 14.9 45 3.5% -0.25 0.066 101 0.11 Silva 2013 66.2 25.3 97 70.7 25.1 107 5.0% -0.25 100 100 101 Silva 2013 66.2 25.3 97 70.7 25.1 107 5.0% -0.75 100 5.0% -0.75 100 100 100 100 100 100 100 100 5.0% 0.05 100 100 100 100 100 100 110 110 100 110 110 100 1100 1100 1100	Sandas-Freitas 2015 63.7 19.3 48 68.1 14.9 45 3.5% -0.25 [0.66] 0.16 2015 Chabra 2013 66.5 23.7 12.3 60 12.6 44 60 0.25 (0.160) 2013 Bansal 2013 66.2 25.3 97 70.7 25.1 107 5.0% -0.18 [-0.45, 0.10] 2013 Bansal 2013 68.9 11.8 31 60.6 15.5 29 2.6% 0.57 [0.06, 1.09] 2013 Holdsas 2011 73.9 17.1 102 71.3 17.6 100 5.0% 0.57 [0.30, 0.43] 2012 Holdsas 2011 48 22 127 46 20.4 123 5.3% 0.09 [0.15, 0.34] 2011 Weir 2011 75.8 124 72.7 5.51 15 5.6% 0.20 [0.03, 0.43] 2011 Bude 2011 71.8 18 146 5.6% 0.055 <td>- </td>	-
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	Chubero 2013 66.5 23.7 123 60 18.2 64 4.6% 0.28 [-0.01, 0.60] 2013 Bansal 2013 66.2 25.3 97 70.7 25.1 107 5.0% 0.18 [-0.46, 0.10] 2013 Bansal 2013 88.9 11.8 31 80.6 16.5 29 2.6% 0.57 [0.06, 1.09] 2013 Holdaas 2011 73.9 17.1 102 71.3 17.6 100 5.0% 0.15 [-0.13, 0.43] 2012 Holdaas 2011 48 22 127 46 2.04 123 5.3% 0.09 [-0.15, 0.34] 2011 Weir 2011 75.5 124 7.12 2.5.3 155 5.6% 0.25 [-0.0, 0.43] 2011 Bude 2011 71.8 154 154 5.6% 0.05 [-0.30, 0.43] 2011 Heiman 2011 64.3 9 2.6 60 0.06 [-0.06, 0.40] 2011	
Silva 2013 66.2 2.5.3 97 70.7 25.1 107 5.0% -0.18 [0-45, 0.10] 2013 Mjörsstelt 2012 7.3.9 17.1 102 71.3 17.6 100 5.0% 0.57 [0.06, 1.09] 2013 Mjörsstelt 2012 7.3.9 17.1 102 71.3 17.6 100 5.0% 0.57 [0.06, 1.09] 2014 Valid 2011 75.5 19.2 148 71.2 23.5% 0.09 [0-15, 0.34] 2011 Weir 2011 75.5 19.2 148 71.2 23.5% 0.09 [0.03, 0.38] 2011 Heliman 2011 64.3 2.9 62.6 28.2 15 5.6% 0.50 [0.20, 0.78] 2010 Guba 2010 64.5 2.52 69 5.4 18 74 4.4% 0.51 [0.77, 0.24] 2009 Schema 2009 59 15.4 555 57.7 15.4 275 6.7% 0.08 [-0.06, 0.23] 2009 Schema 2009 59 15.4 555 57.7 15.4 275 6.7% 0.08 [-0.6, 0.23] 2009	Silva 2013 662 25.3 97 70.7 25.1 107 5.0% -0.18 [-0.45, 0.10] 2013 Mjörnstedt 2012 73.9 17.1 102 71.3 17.6 100 5.0% 0.15 [-0.01, 0.09] 2013 Mjörnstedt 2012 73.9 17.1 102 71.3 17.6 100 5.0% 0.15 [-0.13, 0.43] 2012 Holdsas 2011 48 22 127 46 20.4 123 5.3% 0.09 [-0.15, 0.34] 2011 Weir 2011 75.5 192 148 71.2 25.5 165 5.6% 0.25 [-0.30, 0.43] 2011 Bude 2011 71.8 158 154 6.16 5.6% 0.25 [-0.30, 0.43] 2011 Huiman 2011 64.3 26 62 62 66 0.04 [-0.06, 0.04] 2011	
Barnal 2013 88.9 11.8 31 80.6 16.5 29 2.8% 0.57 (10.06, 1.09) 2013 Mjörnstedt 2017 7.8 17.1 102 71.3 176 100 5.5% 0.15 (-0.13, 0.43) 2011 Holdaas 2011 45 22 127 46 20.4 123 5.5% 0.09 (-0.15, 0.34) 2011 Holdaas 2011 7.8 18 154 61.9 18 146 5.5% 0.02 (0.03, 0.43) 2011 Budde 2011 7.18 18 154 61.9 18 146 5.5% 0.20 (0.03, 0.41) 2011 Guba 2010 64.5 25.2 69 53.4 18 71 4.2% 0.51 (0.07, 0.04) 2011 Lebranchu 2009 65 1.2 0.38 4.4 15 39 3.4% 0.62 (0.06, 0.33) 2009 Total (95% CI) 2721 2344 100.0% 0.20 (0.10, 0.31]	Bansal 2013 88.9 11.8 31 80.6 16.5 2.9 2.6% 0.57 [0.06, 1.09] 2013 Momstedt 2017 73.9 17.1 102 71.3 17.6 100 5.0% 0.15 [-0.13, 0.43] 2012 Holdaas 2011 48 22 127 46 20.4 123 5.3% 0.09 [-0.15, 0.34] 2011 Weir 2011 75. 19.2 148 71.2 25.3 151 5.6% 0.20 [-0.00, 0.43] 2011 Budde 2011 71.8 18 154 61.9 18 146 5.6% 0.055 [0.32, 0.78] 2011 Hulman 2011 64.3 29 62 68 21.6 60 4.0% 0.06 [-0.30 0.41] 2011	
	Mjornšeni 2012 7.3 9 17.1 102 7.3 17.6 100 5.0% 0.05 [0.15 [0.13, 0.43] 2012 Weir 2011 48 22 127 46 20.4 123 5.5% 0.09 [0.15, 0.34] 2011 Weir 2011 75.5 19.2 148 71.2 23.5 151 5.6% 0.20 [-0.03, 0.43] 2011 Budde 2011 71.8 18 154 61.9 18 146 5.6% 0.55 [0.32, 0.78] 2011	
Total (85% Cl) 22 12 46 620 123 5.5% 0.00 [-0.15, 0.23] 201 Heiman 2011 76 72 18 114 6.15 6.5% 0.20 [-0.30, 0.3] 2011 Budde 2011 71.8 18 154 6.15 156 0.20 [-0.30, 0.3] 2011 Guba 2010 64.5 25.2 20 52.2 [-6 0.40% 0.06 [-0.30, 0.41] 2010 Guba 2010 64.5 25.2 20 53.4 18 71 4.2% 0.51 [0.17, 0.40] 2010 Berneiman 2009 65 20 38 44 15 39.3 73.4 0.50 [0.10, 0.31] Lebranchu 2009 61 20 38.4 18 79.7 4.8% 0.64 [0.05, 0.23] 2009 Total (85% Cl) 2721 2344 100.0% 0.20 [0.10, 0.31]	Tholdaes 2011 40 22 12/ 140 204 123 5.3% 0.09 (0.15, 0.34) 2011 Weir 2011 75.5 19.2 148 71.2 23.5 151 5.6% 0.29 (0.03, 0.43) 2011 Budde 2011 71.8 18 154 61.9 18 146 5.6% 0.55 (0.32, 0.78) 2011 Helman 2011 64.3 29 62 63.8 21.6 60 40% 0.06 16.30 0.41 2011	_
Budies 2011 71.8 16 17 16	Budde 2011 71.8 18 154 61.9 18 146 5.6% 0.55 [0.32, 0.78] 2011	
Heiman 2011 643 20 62 62.8 21.8 80 40% 0.06 (-30.041) 2011 Gaba 2010 64.3 22.5 66 30.4 18 71 42% 0.51 (0.17) 2010 Bemelann 2009 55 20 38 44 15 39 3.1% 0.62 (0.16) 10.71 (0.41) 2010 Bemelann 2009 55 20 38 44 15 39 3.1% 0.62 (0.16) 10.71 (0.41) 2010 Schema 2009 51 15.4 555 57.7 15.4 27.5 6.7% 0.08 (0.06, 0.23) 2009 Total (95% Cl) 27.21 23.44 100.0% 0.20 (0.40, 0.31) -	Heilman 2011 64.3 29 62 62 8 21 6 60 4.0% 0.06 [-0.30,0.41] 2011	
Guba 2010 64.5 25.2 69 53.4 18 71 4.2% 0.51 [0.17, 0.24] 2010 Lebranchu 2009 65 53.8 4 15 39 34 16 2010 16 17 0.09 16 17 0.09 16 17 0.09 16 17 0.09 16 17 0.09 16 17 0.09 16 16 10 0.09 10 16 10 0.09 10 10 10 10 16 10 0.09 10 0.00 10 10 10 10 10 10 16 10 10 10 10 10 10 10 10 10 10 10 16 10 <td< td=""><td></td><td></td></td<>		
Bernelman 2009 55 20 38 44 15 39 3.1% 0.62 [0.16, 1.07] 2009 Lebranchu 2009 612 14.6 95 53.9 7 97 44% 0.46 [0.35, 0.33] 2009 Schena 2009 59 15.4 555 57.7 15.4 275 6.7% 0.08 [-0.66, 0.23] 2009 Total (95% CI) 2721 23.44 100.0% 0.20 [0.10, 0.31] -	Guba 2010 64.5 25.2 69 53.4 18 71 4.2% 0.51 [0.17, 0.84] 2010	
Lebranchu 2009 61 21 4.6 95 53.9 7 7 4.8% 0.64 (0.35, 0.33) 2009 Total (95% Cl) 2721 2344 100.% 0.08 (0.06, 0.23) 2009 Total (95% Cl) 2721 2344 100.% 0.20 (0.10, 0.31) - Heterogeneity: Tau*=0.04; Chi* e2.0.8, df = 21 (P < 0.00001); P = 66%	Bemelman 2009 55 20 38 44 15 39 3.1% 0.62 [0.16, 1.07] 2009	
Schena 2009 59 15.4 555 57.7 15.4 275 6.7% 0.08 (-0.60, 0.23) 2009 Total (95% Cl) 2721 2344 100.0% 0.20 (0.10, 0.31) - 1 : : - - - - - - - - - - - - <t< td=""><td>Lebranchu 2009 61.2 14.6 95 53.9 7 97 4.8% 0.64 [0.35, 0.93] 2009</td><td></td></t<>	Lebranchu 2009 61.2 14.6 95 53.9 7 97 4.8% 0.64 [0.35, 0.93] 2009	
Total (95% Ci) 2721 2344 100.0% 0.20 [0.10, 0.31] Heterogeneity: Tau ² = 0.04; Chi ² = 62.08, df = 21 (P < 0.0001); P = 66%	Schena 2009 59 15.4 555 57.7 15.4 275 6.7% 0.08 [-0.06, 0.23] 2009	-
Dual (19% U) U <t< td=""><td>T-4-1 (05% CI) 0704 0040 00% 0.00 (0.0.0.0.1)</td><td>▲</td></t<>	T-4-1 (05% CI) 0704 0040 00% 0.00 (0.0.0.0.1)	▲
Test for overline Status	$\frac{1}{2} \frac{1}{2} \frac{1}$	• + + +
Experimental Study or Subgroup Experimental Formation Control Risk Ratio Risk Ratio Risk Ratio Study or Subgroup Events Total Events Total Vents Vents Total <td< td=""><td>The term of the term of term</td><td>1 2</td></td<>	The term of term	1 2
Experimental Control Risk Ratio Risk Ratio Risk Ratio Study or Subgroup Total Events Total Versits MHL Random. 95% CI Year MHL Random. 95% CI Year MHL Random. 95% CI Year Tönshoff 2019 7 52 1 54 1.4% 7.27 (0.93, 57.06) 2019 Taber 2019 0 0 0 Versits Note stimable 2019 Boumar 2018 9 30 2 30 2.4% Note stimable 2019 Boumar 2018 9 197 6 197 4.50 (1.06, 19.11) 2018 Bemelman 2017 12 96 197 4.83 (5.05, 11.33) 2017	Favours CNI F	Favours mTORi
Study or Subgroup Events Total Events Total Weight M-H. Random, 95% Cl Year M-H. Random, 95% Cl Year Torshoff 2019 7 52 1 54 1.4% 7.27 (0.93, 57.06) 2019	Experimental Control Risk Ratio Risk	Ratio
Tonshoff 2019 7 52 1 54 1.4% 7.27 [0.93, 57.06] 2019 Brakemeier 2019 12 51 52 4 4.4% 1.13 (0.45, 2.84] 2019 Taber 2019 0 0 0 Not estimable 2019 Boumanr 2018 9 30 2 30 2.4% 4.50 (10.6, 19.11) 2018 Haynes 2018 29 197 6 197 4.7% 4.83 [2.05, 11.38] 2018 Bernelman 2017 12 96 17 89 5.9% 0.05 [0.33, 1.29] 2017 Filjer 2017 39 399 21 366 7.1% 1.84 [1.11, 3.07] 2017 Filjer 2017 39 399 21 366 7.1% 1.84 [1.11, 3.07] 2017 Freitz 2016 35 0.36 Rot simable 2016 - - Pretagostini 2016 2 24 3 25 1.3.38] 2016 - Budde 2015 <td< td=""><td>Study or Subgroup Events Total Events Total Weight M-H, Random, 95% CI Year M-H, Random</td><td>dom. 95% Cl</td></td<>	Study or Subgroup Events Total Events Total Weight M-H, Random, 95% CI Year M-H, Random	dom. 95% Cl
Brakemeier 2019 12 51 5 24 4.4% 1.13 [0.45, 2.84] 2019 Brakemeier 2019 0 0 0 Notestimable 2019 Boumar 2018 9 30 2 30 2.4% 4.50 [1.06, 19.11] 2018 Haynes 2018 9 197 6 197 4.50 [5.03, 1.29] 2017 Bemelman 2017 12 96 17 89 5.9% 0.65 [0.33, 1.29] 2017 Guida 2017 17 13 165 6.0% 1.48 [0.76, 2.89] 2017 Chuzado 2016 35 0 36 Note stimable 2016 Pretagostini 2016 2 59 2.3% 4.42 [1.00, 19.62] 2016 Pretagostini 2016 2 59 2.3% 4.44 [1.01, 19.50] 2016 Pretagostini 2015 12 92 10 90 5.2% 1.17 [0.53, 2.58] 2015 Sandes-Freitas 2015 4 86 0.45 0.7% 1.90 [1.01, 3.76]	Tönshoff 2019 7 52 1 54 1.4% 7.27 [0.93, 57.06] 2019	
Tabler 2019 0 0 0 0 Not estimable 2019 Bouramar 2018 9 30 2 30 2.4% 4.50 [10.6, 19.11] 2018 Haynes 2018 29 197 6 197 4.7% 4.83 [2.05, 11.38] 2018 Bemelman 2017 12 96 17 89 5.9% 0.56 [0.33, 1.29] 2017 Budde 2017 20 171 13 165 6.0% 1.48 [0.76, 2.89] 2017 Cruzado 2016 0 35 0 36 Not estimable 2016 Felix 2016 9 60 2 59 2.3% 4.42 [1.00, 19.62] 2016 Pretagostini 2016 2 24 3 25 1.9% 0.59 [0.13, 3.80] 2016 Budde 2015 0 46 0 47 Not estimable 2015 Rostaing 2015 24 96 5 98 4.4% 4.90 [1.05, 12.31] 2015 Sandes-Freitas 2015	Brakemeier 2019 12 51 5 24 4.4% 1.13 [0.45, 2.84] 2019	
Bournar 2018 9 30 2 30 2.4% 4.50 [1.06, 19.11] 2018 Haynes 2018 29 197 6 197 4.50 [5.05, 11.38] 2018 Bemelman 2017 12 96 17 89 5.9% 0.65 [0.33, 1.29] 2017 Bemelman 2017 10 171 18 165 0.76, 2.89] 2017 Fijler 2017 39 359 21 356 7.1% 1.84 [1.11, 3.07] 2017 Cnuzado 2016 0 35 0 36 Not estimable 2016 Pretagostini 2016 2 24 3 25 1.9% 0.69 [0.13, 3.80] 2016 Budde 2015 0 46 0 47 Not estimable 2015	Taber 2019 0 0 0 0 Not estimable 2019	
Haynes 2018 29 197 6 197 4.7% 4.85 [2.05, 11.38] 2018 Bernelman 2017 12 96 17 89 5.9% 0.56 [0.33, 1.29] 2017 Budde 2017 20 171 13 165 6.0% 1.48 [0.76, 2.89] 2017 Filer 2017 39 359 21 356 7.1% 1.34 [1.11, 3.07] 2017 Cruzado 2016 0 35 0 36 Not estimable 2016 Felix 2016 9 6.0 4.22 [1.00, 19.62] 2016 Pretagostini 2016 2 24 3 25 1.5% 0.59 [0.13, 3.80] 2016 Budde 2015 0 4.6 0 47 Not estimable 2016 Rostaing 2015 24 96 5 98 4.4% 4.90 [1.95, 12.31] 2015 Rostaing 2015 24 96 5 98 4.4% 4.90 [1.95, 12.31] 2015 Bansal 2013 0 31 2 29 7% 0.19 [0.01, 3.75] 2013 Chabra 201	Bouamar 2018 9 30 2 30 2.4% 4.50 [1.06, 19.11] 2018	
Bernemina 2017 12 96 17 89 5.5% 0.05 (0.33, 1.29) 2017 Builde 2017 20 171 13 165 6.0% 1.48 (0.76, 2.89) 2017 Fijler 2017 39 359 21 356 7.1% 1.84 (1.11, 3.07) 2017 Cruzado 2016 0 35 0 36 Not estimable 2016 Pretapositin 2016 2 24 3 25 1.9% 0.69 (0.13, 3.80) 2016 Budde 2015 0 46 0 47 Not estimable 2015 10 Mjörnsteut 2015 12 92 10 90 5.2% 1.17 (0.53, 2.58) 2015	Haynes 2018 29 197 6 197 4.7% 4.83 [2.05, 11.38] 2018	
Budde 2017 20 171 13 165 6.0% 148 [0.76, 289] 2017 Fijler 2017 39 359 21 366 7.1% 1.44 [1.11, 3.07] 2017 Cruzado 2016 0 35 0 36 Not estimable 2016 Pretagostimi 2016 2 24 3 25 1.5% 0.069 [0.13, 3.80] 2016 Budde 2015 0 46 0 47 Not estimable 2016 Sandes-Freitas 2015 12 92 10 90 5.2% 1.17 [0.53, 2.58] 2015 Sandes-Freitas 2015 4 86 0.45 0.7% 0.49 [0.10, 3.76] 2015 Sandes-Freitas 2015 4 48 0 45 0.7% 0.19 [0.10, 3.76] 2015 Sandes-Freitas 2015 4 48 0.45 0.7% 0.19 [0.10, 3.76] 2015 Chabra 2013 0 31 2 29 0.7% 0.19 [0.10, 3.76] 2013 Silva 2013 <td>Berneiman 2017 12 96 17 89 5.9% 0.65 [0.33, 1.29] 2017</td> <td>L</td>	Berneiman 2017 12 96 17 89 5.9% 0.65 [0.33, 1.29] 2017	L
Fight 2017 39 399 21 356 7.1% 1.24 [1,11, 3.07] 2017 Cruzado 2016 0 35 0 36 Not estimable 2016 Felix 2016 9 60 2 59 2.3% 4.42 [1.00, 19.62] 2016 Pretagostini 2016 2 24 3 25 1.9% 0.69 [0.13, 3.80] 2016 Budde 2015 0 46 0 47 Not estimable 2016 Mjörnstedt 2015 12 92 10 90 5.2% 1.17 [0.53, 2.58] 2015 Sandes-Freits 2015 24 96 5 98 4.4% 4.90 [1.05, 12.31] 2015 Sandes-Freits 2015 4 48 0 45 0.7% 0.19 [0.01, 3.76] 2015 Sandes-Freits 2015 4 48 0 45 0.07% 0.19 [0.01, 3.76] 2013 Chabra 2013 03 12 29 0.7% 0.19 [0.00, 3.76] 2013 Silw	Budde 2017 20 171 13 165 6.0% 1.48 [0.76, 2.89] 2017	-
Chilzabla 2016 0 35 0 36 Field 2016 2016 Pretagostini 2016 2 24 3 25 1.9% 4.42 [10.0, 19.62] 2016 Pretagostini 2016 2 24 3 25 1.9% 0.69 [0.13, 3.80] 2016 Budde 2015 0 46 0 47 Not estimable 2015	File 2017 39 359 21 350 7.1% 1.04 [1.1], 3.07] 2017	
Pentagositi 2016 2 39 2.5% 4.42 [1.00, 13.02] 2016 Pretagositi 2016 2 24 3 25 1.9% 0.05 [1.03, 3.80] 2016 Budde 2015 0 4.6 0 47 Not estimable 2015 Rostaing 2015 2 96 5 98 4.4% 4.90 [1.95, 1.23] 2015 Rostaing 2015 24 96 5 98 4.4% 4.90 [1.95, 1.23] 2015 Bansal 2013 0 31 2 29 0.7% 0.49 [0.01, 3.76] 2013 Chabra 2013 12 123 6 64 4.3% 1.04 [0.01, 3.76] 2013		<u> </u>
Autogoalini 2015 0 48 0 47 Not estimable 2015 Mjörnstedt 2015 12 92 10 90 5.2% 1.17 [0.53, 2.56] 2015 Mjörnstedt 2015 12 92 10 90 5.2% 1.07 [0.53, 2.56] 2015 Sandes-Freitas 2015 4 48 0 45 0.7% 0.19 [0.01, 3.75] 2015 Sandes-Freitas 2015 4 48 0 45 0.7% 0.19 [0.01, 3.75] 2015 Sandes-Freitas 2013 0 31 2 29 0.7% 0.19 [0.01, 3.75] 2013 Chabra 2013 12 12.3 6 64 4.3% 1.04 [0.41, 2.64] 2013	Pertagostini 2016 2 24 3 25 10% 0.69 [0.13.3.80] 2016	<u> </u>
Database 2015 Control	Fieldosum 2010 2 24 3 23 1.9% 0.05 [0.10, 3.00] 2010	
Applications Cite	Nigenstant 2015 12 92 10 90 5.2% 1.17(10.53, 2.58) 2015	
Sandes-Freitas 2015 4 48 0 45 0.7% 8.45 [0.47, 152.62] 2015 Bansal 2013 0 31 2 29 0.7% 0.19 [0.01, 3.75] 2013 Chiabra 2013 12 123 6 64 4.3% 1.04 [0.41, 2.64] 2013 Silva 2013 28 97 24 107 7.4% 129 [0.00, 2.06] 2013	Rostaing 2015 24 96 5 98 44% 490 [195, 12.31] 2015	
Bansal 2013 0 31 2 29 0.7% 0.19 [0.01, 3.75] 2013 Chiabra 2013 12 123 6 64 4.3% 1.04 [0.41, 2.64] 2013 Silva 2013 28 97 24 107 7.4% 1.29 [0.00, 2.06] 2013	Sandes-Freitas 2015 4 48 0 45 0 47% 8 45 [0 47, 126 62] 2015	+
Chhabra 2013 12 123 6 64 4.3% 1.04 [0.41, 2.64] 2013 Silva 2013 28 97 24 107 74% 1.29 [0.80, 206] 2013	Bansal 2013 0 31 2 29 0.7% 0.19 (0.01.3.75) 2013	+-
Silva 2013 28 97 24 107 7.4% 1.29 [0.80, 2.06] 2013	Chhabra 2013 12 123 6 64 4.3% 1.04 [0.41, 2.64] 2013	+-
	Silva 2013 28 97 24 107 7.4% 1.29 [0.80, 2.06] 2013	+-
Mjörnstedt 2012 28 102 11 100 6.1% 2.50 [1.32, 4.74] 2012	Mjörnstedt 2012 28 102 11 100 6.1% 2.50 [1.32, 4.74] 2012	
Budde 2011 23 154 22 146 6.9% 0.99 [0.58, 1.70] 2011	Budde 2011 23 154 22 146 6.9% 0.99 [0.58, 1.70] 2011	+
Heilman 2011 8 62 1 60 1.4% 7.74 [1.00, 60.04] 2011	Heilman 2011 8 62 1 60 1.4% 7.74 [1.00, 60.04] 2011	
Holdaas 2011 7 127 3 123 2.7% 2.26 [0.60, 8.54] 2011	Holdaas 2011 7 127 3 123 2.7% 2.26 [0.60, 8.54] 2011	+
Weir 2011 14 148 17 151 5.9% 0.84 [0.43, 1.64] 2011	Weir 2011 14 148 17 151 5.9% 0.84 [0.43, 1.64] 2011	+
Guba 2010 12 69 11 71 5.4% 1.12 [0.53, 2.37] 2010	Guba 2010 12 69 11 71 5.4% 1.12 [0.53, 2.37] 2010	+
Bemelman 2009 0 38 1 39 0.6% 0.34 [0.01, 8.14] 2009	Bemelman 2009 0 38 1 39 0.6% 0.34 [0.01, 8.14] 2009	<u> </u>
Lebranchu 2009 16 95 8 97 5.1% 2.04 [0.92, 4.55] 2009	Lebranchu 2009 16 95 8 97 5.1% 2.04 [0.92, 4.55] 2009	
Schena 2009 44 555 19 275 7.1% 1.15 [0.68, 1.93] 2009	Schena 2009 44 555 19 275 7.1% 1.15 [0.68, 1.93] 2009	+
Stallone 2005 0 34 0 50 Not estimable 2005		
	Stallone 2005 0 34 0 50 Not estimable 2005	
Total (95% Cl) 2992 2627 100.0% 1.58 [1.22, 2.04]	Stallone 2005 0 34 0 50 Not estimable 2005	•
Total events 371 210	Stallone 2005 0 34 0 50 Not estimable 2005 Total (8% Cl) 2992 2627 100.0% 1.58 [1.22, 2.04]	<u> </u>
Heterogeneity: I au = 0.17; Chr = 46.14, dt = 23 (P = 0.003); P = 50%	Stallone 2005 0 34 0 50 Not estimable 2005 Total (95% Cl) 2992 2627 100.0% 1.58 [1.22, 2.04] 1 Total events 371 210 0.000 p. 500 1 1 1	

FIGURE 3 | The forest plot of studies that compared conversion from CNIs to mTOR inhibitors versus maintenance of CNI therapy for the outcomes of (A) graft loss and (B) mortality.

conversion should be KTRs with a baseline GFR of more than 40 ml/min and normal urinary protein excretion, an absence of previous AR and subclinical rejection, and appearance of donor-specific antibody (14, 25). Periodic surveillance biopsies may also help to identify a subset of KTRs who do not develop subclinical rejection or irreversible pathological changes in the renal interstitial to guide mTORi conversion therapy (56).

The high rate of drug discontinuation in the conversion group illustrates the challenge of handling a new spectrum of AEs that differs from more familiar CNI-related AEs, including dyslipidemia, acne, mouth ulceration, proteinuria, and AR (57, 58). Most AEs occurred early after conversion and in some cases resolved without intervention within a few weeks. Some of the discontinuations in the conversion group could have been avoided with better patient selection and more refined management of mTORi-related AEs. Specific patient monitoring and the concomitant use of lipid-lowering agents, angiotensin-converting-enzyme inhibitors, angiotensin receptor blockers, and induction therapies should be considered for combating dyslipidemia, proteinuria, and AR (16, 59). The identification of the optimal timing of conversion, appropriate candidates, dosing regimens for conversion, and safe management of mTORi-related AEs will be key in minimizing the need for discontinuation, which currently limits the broad applicability of this strategy.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/**Supplementary Material**. Further inquiries can be directed to the corresponding authors.

AUTHOR CONTRIBUTIONS

JZ designed the study and wrote the manuscript. XF, QZ, and LL performed the meta-analysis and did the data extraction. SF, YF, TS, and ZH checked the results. XW and TL designed the

research strategy and revised the manuscript. All authors reviewed the manuscript. All authors contributed to the article and approved the submitted version.

FUNDING

This study was supported by grants from the Sichuan Science and Technology Program [grant number 2019YJ0133]; Chengdu Science and Technology Program [grant number 2019-YF05-

REFERENCES

- Lamb KE, Lodhi S, Meier-Kriesche HU. Long-Term Renal Allograft Survival in the United States: A Critical Reappraisal. *Am J Transpl* (2011) 11(3):450– 62. doi: 10.1111/j.1600-6143.2010.03283.x
- Vincenti F. Are Calcineurin Inhibitors-Free Regimens Ready for Prime Time? Kidney Int (2012) 82(10):1054–60. doi: 10.1038/ki.2012.194
- Maluf DG, Dumur CI, Suh JL, Lee JK, Cathro HP, King AL, et al. Evaluation of Molecular Profiles in Calcineurin Inhibitor Toxicity Post-Kidney Transplant: Input to Chronic Allograft Dysfunction. *Am J Transpl* (2014) 14(5):1152–63. doi: 10.1111/ajt.12696
- Mourer JS, de Koning EJ, van Zwet EW, Mallat MJ, Rabelink TJ, de Fijter JW. Impact of Late Calcineurin Inhibitor Withdrawal on Ambulatory Blood Pressure and Carotid Intima Media Thickness in Renal Transplant Recipients. *Transplantation* (2013) 96(1):49–57. doi: 10.1097/TP. 0b013e3182958552
- 5. Mohan S, Hirsch J. Risk of Malignancy After Renal Transplantation. *Transplantation* (2013) 95(1):17–8. doi: 10.1097/TP.0b013e31827b3d70
- Sharif A, Shabir S, Chand S, Cockwell P, Ball S, Borrows R. Meta-Analysis of Calcineurin-Inhibitor-Sparing Regimens in Kidney Transplantation. J Am Soc Nephrol (2011) 22(11):2107–18. doi: 10.1681/ASN.2010111160
- Sutherland AI, Akhtar MZ, Zilvetti M, Brockmann J, Ruse S, Fuggle SV, et al. Alemtuzumab and Sirolimus in Renal Transplantation: Six-Year Results of a Single-Arm Prospective Pilot Study. *Am J Transpl* (2014) 14(3):677–84. doi: 10.1111/ajt.12572
- Russ G, Segoloni G, Oberbauer R, Legendre C, Mota A, Eris J, et al. Superior Outcomes in Renal Transplantation After Early Cyclosporine Withdrawal and Sirolimus Maintenance Therapy, Regardless of Baseline Renal Function. *Transplantation* (2005) 80(9):1204–11. doi: 10.1097/01.tp.0000178393.78084.9b
- Webster AC, Lee VW, Chapman JR, Craig JC. Target of Rapamycin Inhibitors (Sirolimus and Everolimus) for Primary Immunosuppression of Kidney Transplant Recipients: A Systematic Review and Meta-Analysis of Randomized Trials. *Transplantation* (2006) 81(9):1234–48. doi: 10.1097/ 01.tp.0000219703.39149.85
- Peddi VR, Wiseman A, Chavin K, Slakey D. Review of Combination Therapy With mTOR Inhibitors and Tacrolimus Minimization After Transplantation. *Transplant Rev (Orlando)* (2013) 27(4):97–107. doi: 10.1016/j.trre.2013.06.001
- Webster AC, Lee VW, Chapman JR, Craig JC. Target of Rapamycin Inhibitors (TOR-I; Sirolimus and Everolimus) for Primary Immunosuppression in Kidney Transplant Recipients. *Cochrane Database Syst Rev* (2006) (2): CD004290. doi: 10.1002/14651858.CD004290.pub2
- Nashan B, Citterio F. Wound Healing Complications and the Use of Mammalian Target of Rapamycin Inhibitors in Kidney Transplantation: A Critical Review of the Literature. *Transplantation* (2012) 94(6):547–61. doi: 10.1097/TP.0b013e3182551021
- Morath C, Arns W, Schwenger V, Mehrabi A, Fonouni H, Schmidt J, et al. Sirolimus in Renal Transplantation. *Nephrol Dialysis Transpl* (2007) 22(Supplement 8):viii61–5. doi: 10.1093/ndt/gfm652
- Gatault P, Lebranchu Y. Conversion to mTOR-Inhibitor-Based Immunosuppression: Which Patients and When? *Transplant Res* (2013) 2 (Suppl 1):S3. doi: 10.1186/2047-1440-2-S1-S3
- 15. Budde K, Becker T, Arns W, Sommerer C, Reinke P, Eisenberger U, et al. Everolimus-Based, Calcineurin-Inhibitor-Free Regimen in Recipients of

00084-SN]; and 1.3.5 Project for Disciplines of Excellence-Clinical Research Incubation Project, West China Hospital, Sichuan University [grant number 2019-075, ZY2016104, 2021HXFH007].

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2021.663602/full#supplementary-material

De-Novo Kidney Transplants: An Open-Label, Randomised, Controlled Trial. Lancet (2011) 377(9768):837–47. doi: 10.1016/S0140-6736(10)62318-5

- Claes K, Meier-Kriesche HU, Schold JD, Vanrenterghem Y, Halloran PF, Ekberg H, et al. Effect of Different Immunosuppressive Regimens on the Evolution of Distinct Metabolic Parameters: Evidence From the Symphony Study. Nephrol Dial Transpl (2012) 27(2):850–7. doi: 10.1093/ndt/gfr238
- Holdaas H, Rostaing L, Seron D, Cole E, Chapman J, Fellstrom B, et al. Conversion of Long-Term Kidney Transplant Recipients From Calcineurin Inhibitor Therapy to Everolimus: A Randomized, Multicenter, 24-Month Study. *Transplantation* (2011) 92(4):410–8. doi: 10.1097/TP.0b013 e318224c12d
- Mulay AV, Cockfield S, Stryker R, Fergusson D, Knoll GA. Conversion From Calcineurin Inhibitors to Sirolimus for Chronic Renal Allograft Dysfunction: A Systematic Review of the Evidence. *Transplantation* (2006) 82(9):1153–62. doi: 10.1097/01.tp.0000237101.58974.43
- Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. J Clin Epidemiol (2009) 62(10):1006–12. doi: 10.1016/j.jclinepi.2009.06.005
- Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's Tool for Assessing Risk of Bias in Randomised Trials. *BMJ* (2011) 343:d5928. doi: 10.1136/bmj.d5928
- Stallone G, Infante B, Schena A, Battaglia M, Ditonno P, Loverre A, et al. Rapamycin for Treatment of Chronic Allograft Nephropathy in Renal Transplant Patients. J Am Soc Nephrol (2005) 16(12):3755–62. doi: 10.1681/ ASN.2005060635
- Liu M, Zhang W, Gu M, Yin C, Zhang WY, Lv Q, et al. Protective Effects of Sirolimus by Attenuating Connective Tissue Growth Factor Expression in Human Chronic Allograft Nephropathy. *Transplant Proc* (2007) 39(5):1410– 5. doi: 10.1016/j.transproceed.2007.03.072
- Bemelman FJ, de Maar EF, Press RR, van Kan HJ, ten Berge IJ. Minimization of Maintenance Immunosuppression Early After Renal Transplantation: An Interim Analysis. *Transplantation* (2009) 88(3):421–8. doi: 10.1097/ TP.0b013e3181af1df6
- Lebranchu Y, Thierry A, Toupance O, Westeel PF, Etienne I, Thervet E, et al. Efficacy on Renal Function of Early Conversion From Cyclosporine to Sirolimus 3 Months After Renal Transplantation: Concept Study. Am J Transpl (2009) 9(5):1115–23. doi: 10.1111/j.1600-6143.2009.02615.x
- 25. Schena FP, Pascoe MD, Alberu J, del Carmen Rial M, Oberbauer R, Brennan DC, et al. Conversion From Calcineurin Inhibitors to Sirolimus Maintenance Therapy in Renal Allograft Recipients: 24-Month Efficacy and Safety Results From the CONVERT Trial. *Transplantation* (2009) 87(2):233–42. doi: 10.1097/TP.0b013e3181927a41
- 26. Guba M, Pratschke J, Hugo C, Kramer BK, Nohr-Westphal C, Brockmann J, et al. Renal Function, Efficacy, and Safety of Sirolimus and Mycophenolate Mofetil After Short-Term Calcineurin Inhibitor-Based Quadruple Therapy in De Novo Renal Transplant Patients: One-Year Analysis of a Randomized Multicenter Trial. *Transplantation* (2010) 90(2):175–83. doi: 10.1097/TP.0b013e3181e11798
- Heilman RL, Younan K, Wadei HM, Mai ML, Reddy KS, Chakkera HA, et al. Results of a Prospective Randomized Trial of Sirolimus Conversion in Kidney Transplant Recipients on Early Corticosteroid Withdrawal. *Transplantation* (2011) 92(7):767–73. doi: 10.1097/TP.0b013e31822805d7
- Weir MR, Mulgaonkar S, Chan L, Shidban H, Waid TH, Preston D, et al. Mycophenolate Mofetil-Based Immunosuppression With Sirolimus in Renal

Transplantation: A Randomized, Controlled Spare-The-Nephron Trial. *Kidney Int* (2011) 79(8):897–907. doi: 10.1038/ki.2010.492

- Mjornstedt L, Sorensen SS, von Zur Muhlen B, Jespersen B, Hansen JM, Bistrup C, et al. Improved Renal Function After Early Conversion From a Calcineurin Inhibitor to Everolimus: A Randomized Trial in Kidney Transplantation. Am J Transpl (2012) 12(10):2744–53. doi: 10.1111/j.1600-6143.2012.04162.x
- Bansal D, Yadav AK, Kumar V, Minz M, Sakhuja V, Jha V. Deferred Pre-Emptive Switch From Calcineurin Inhibitor to Sirolimus Leads to Improvement in GFR and Expansion of T Regulatory Cell Population: A Randomized, Controlled Trial. *PLoS One* (2013) 8(10):e75591. doi: 10.1371/ journal.pone.0075591
- 31. Chhabra D, Alvarado A, Dalal P, Leventhal J, Wang C, Sustento-Reodica N, et al. Impact of Calcineurin-Inhibitor Conversion to mTOR Inhibitor on Renal Allograft Function in a Prednisone-Free Regimen. *Am J Transpl* (2013) 13(11):2902–11. doi: 10.1111/ajt.12437
- 32. Silva HTJr, Felipe CR, Garcia VD, Neto ED, Filho MA, Contieri FL, et al. Planned Randomized Conversion From Tacrolimus to Sirolimus-Based Immunosuppressive Regimen in De Novo Kidney Transplant Recipients. *Am J Transpl* (2013) 13(12):3155–63. doi: 10.1111/ajt.12481
- 33. Budde K, Rath T, Sommerer C, Haller H, Reinke P, Witzke O, et al. Renal, Efficacy and Safety Outcomes Following Late Conversion of Kidney Transplant Patients From Calcineurin Inhibitor Therapy to Everolimus: The Randomized APOLLO Study. *Clin Nephrol* (2015) 83(1):11–21. doi: 10.5414/CN108444
- 34. de Sandes-Freitas TV, Felipe CR, Campos EF, de Lima MG, Soares MF, de Franco MF, et al. Subclinical Lesions and Donor-Specific Antibodies in Kidney Transplant Recipients Receiving Tacrolimus-Based Immunosuppressive Regimen Followed by Early Conversion to Sirolimus. *Transplantation* (2015) 99(11):2372–81. doi: 10.1097/TP.00000000000748
- 35. Mjornstedt L, Schwartz Sorensen S, von Zur Muhlen B, Jespersen B, Hansen JM, Bistrup C, et al. Renal Function Three Years After Early Conversion From a Calcineurin Inhibitor to Everolimus: Results From a Randomized Trial in Kidney Transplantation. *Transpl Int* (2015) 28(1):42–51. doi: 10.1111/tri.12437
- 36. Rostaing L, Hertig A, Albano L, Anglicheau D, Durrbach A, Vuiblet V, et al. Fibrosis Progression According to Epithelial-Mesenchymal Transition Profile: A Randomized Trial of Everolimus Versus CsA. Am J Transpl (2015) 15 (5):1303–12. doi: 10.1111/ajt.13132
- Cruzado JM, Pascual J, Sanchez-Fructuoso A, Seron D, Diaz JM, Rengel M, et al. Controlled Randomized Study Comparing the Cardiovascular Profile of Everolimus With Tacrolimus in Renal Transplantation. *Transpl Int* (2016) 29 (12):1317–28. doi: 10.1111/tri.12862
- Felix MJ, Felipe CR, Tedesco-Silva H, Osmar Medina-Pestana J. Time-Dependent and Immunosuppressive Drug-Associated Adverse Event Profiles in De Novo Kidney Transplant Recipients Converted From Tacrolimus to Sirolimus Regimens. *Pharmacotherapy* (2016) 36(2):152–65. doi: 10.1002/phar.1692
- Pretagostini R, Poli L, Pettorini L, Lai Q, Garofalo M, Melandro F, et al. Delayed Introduction of Everolimus in De Novo Renal Transplanted Patients: A Single-Center Experience. *Transplant Proc* (2016) 48(2):326–8. doi: 10.1016/j.transproceed.2016.02.004
- Bemelman FJ, de Fijter JW, Kers J, Meyer C, Peters-Sengers H, de Maar EF, et al. Early Conversion to Prednisolone/Everolimus as an Alternative Weaning Regimen Associates With Beneficial Renal Transplant Histology and Function: The Randomized-Controlled MECANO Trial. Am J Transpl (2017) 17(4):1020–30. doi: 10.1111/ajt.14048
- Budde K, Zeier M, Witzke O, Arns W, Lehner F, Guba M, et al. Everolimus With Cyclosporine Withdrawal or Low-Exposure Cyclosporine in Kidney Transplantation From Month 3: A Multicentre, Randomized Trial. *Nephrol Dial Transpl* (2017) 32(6):1060–70. doi: 10.1093/ndt/gfx075
- 42. de Fijter JW, Holdaas H, Oyen O, Sanders JS, Sundar S, Bemelman FJ, et al. Early Conversion From Calcineurin Inhibitor- to Everolimus-Based Therapy Following Kidney Transplantation: Results of the Randomized ELEVATE Trial. Am J Transpl (2017) 17(7):1853–67. doi: 10.1111/ajt.14186
- 43. Bouamar R, Shuker N, Osinga JAJ, Groningen MCC-v, Wetering Jvd, Rowshani AT, et al. Conversion From Tacrolimus to Everolimus With

Complete and Early Glucocorticoid Withdrawal After Kidney Transplantation: A Randomised Trial. *Netherlands J Med* (2018) 76(1):14–26.

- 44. Group CSC. Campath, Calcineurin Inhibitor Reduction, and Chronic Allograft Nephropathy (The 3C Study) - Results of a Randomized Controlled Clinical Trial. Am J Transpl (2018) 18(6):1424–34. doi: 10.1111/ ajt.14619
- 45. Brakemeier S, Arns W, Lehner F, Witzke O, Vonend O, Sommerer C, et al. Everolimus in De Novo Kidney Transplant Recipients Participating in the Eurotransplant Senior Program: Results of a Prospective Randomized Multicenter Study (SENATOR). *PLoS One* (2019) 14(9):e0222730. doi: 10.1371/journal.pone.0222730
- 46. Taber DJ, Chokkalingam A, Su Z, Self S, Miller D, Srinivas T. Randomized Controlled Trial Assessing the Impact of Everolimus and Low-Exposure Tacrolimus on Graft Outcomes in Kidney Transplant Recipients. *Clin Transpl* (2019) 33(10):e13679. doi: 10.1111/ctr.13679
- 47. Tonshoff B, Ettenger R, Dello Strologo L, Marks SD, Pape L, Tedesco-Silva H Jr, et al. Early Conversion of Pediatric Kidney Transplant Patients to Everolimus With Reduced Tacrolimus and Steroid Elimination: Results of a Randomized Trial. Am J Transpl (2019) 19(3):811–22. doi: 10.1111/ajt.15081
- Franz S, Regeniter A, Hopfer H, Mihatsch M, Dickenmann M. Tubular Toxicity in Sirolimus- and Cyclosporine-Based Transplant Immunosuppression Strategies: An Ancillary Study From a Randomized Controlled Trial. Am J Kidney Dis (2010) 55(2):335-43. doi: 10.1053/ j.ajkd.2009.09.004
- Har A, Smith JM, Skeans MA, Gustafson SK, Wilk AR, Robinson A, et al. OPTN/SRTR 2016 Annual Data Report: Kidney. *Am J Transpl* (2018) 18:18– 113. doi: 10.1111/ajt.14557
- 50. Wolf S, Hoffmann VS, Habicht A, Kauke T, Bucher J, Schoenberg M, et al. Effects of mTOR-Is on Malignancy and Survival Following Renal Transplantation: A Systematic Review and Meta-Analysis of Randomized Trials With a Minimum Follow-Up of 24 Months. *PLoS One* (2018) 13(4): e0194975. doi: 10.1371/journal.pone.0194975
- 51. Sanchez-Escuredo A, Diekmann F, Revuelta I, Esforzado N, Ricart MJ, Cofan F, et al. An mTOR-Inhibitor-Based Protocol and Calcineurin Inhibitor (CNI)-Free Treatment in Kidney Transplant Recipients From Donors After Cardiac Death: Good Renal Function, But High Incidence of Conversion to CNI. *Transpl Int* (2016) 29(3):362–8. doi: 10.1111/tri.12732
- Glover TE, Watson CJ, Gibbs P, Bradley JA, Ntzani EE, Kosmoliaptsis V. Conversion From Calcineurin to Mammalian Target of Rapamycin Inhibitors in Liver Transplantation: A Meta-Analysis of Randomized Controlled Trials. *Transplantation* (2016) 100(3):621–9. doi: 10.1097/TP.0000000000001006
- 53. Lim WH, Eris J, Kanellis J, Pussell B, Wiid Z, Witcombe D, et al. A Systematic Review of Conversion From Calcineurin Inhibitor to Mammalian Target of Rapamycin Inhibitors for Maintenance Immunosuppression in Kidney Transplant Recipients. Am J Transpl (2014) 14(9):2106–19. doi: 10.1111/ ajt.12795
- Wolf S, Lauseker M, Schiergens T, Wirth U, Drefs M, Renz B, et al. Infections After Kidney Transplantation: A Comparison of mTOR-Is and CNIs as Basic Immunosuppressants. A Systematic Review and Meta-Analysis. *Transpl Infect Dis* (2020) 22(3):e13267. doi: 10.1111/tid.13267
- 55. Chaabane A, Aouam K, Ben Fredj N, Hammouda M, Chadly Z, El May M, et al. Limited Sampling Strategy of Mycophenolic Acid in Adult Kidney Transplant Recipients: Influence of the Post-Transplant Period and the Pharmacokinetic Profile. *J Clin Pharmacol* (2013) 53(9):925–33. doi: 10.1002/jcph.125
- 56. Thierry A, Thervet E, Vuiblet V, Goujon JM, Machet MC, Noel LH, et al. Long-Term Impact of Subclinical Inflammation Diagnosed by Protocol Biopsy One Year After Renal Transplantation. *Am J Transpl* (2011) 11 (10):2153–61. doi: 10.1111/j.1600-6143.2011.03695.x
- Ekberg H, Bernasconi C, Noldeke J, Yussim A, Mjornstedt L, Erken U, et al. Cyclosporine, Tacrolimus and Sirolimus Retain Their Distinct Toxicity Profiles Despite Low Doses in the Symphony Study. *Nephrol Dial Transpl* (2010) 25(6):2004–10. doi: 10.1093/ndt/gfp778
- Hamdy AF, Bakr MA, Ghoneim MA. Long-Term Efficacy and Safety of a Calcineurin Inhibitor-Free Regimen in Live-Donor Renal Transplant Recipients. J Am Soc Nephrol (2008) 19(6):1225–32. doi: 10.1681/ ASN.2007091001

 Guerra G, Ciancio G, Gaynor JJ, Zarak A, Brown R, Hanson L, et al. Randomized Trial of Immunosuppressive Regimens in Renal Transplantation. J Am Soc Nephrol (2011) 22(9):1758-68. doi: 10.1681/ ASN.2011010006

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of

the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Zeng, Zhong, Feng, Li, Feng, Fan, Song, Huang, Wang and Lin. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.